YPN 005
Alternative Names: YPN-005Latest Information Update: 28 Jan 2025
At a glance
- Originator Yungjin Pharm Co
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Triple negative breast cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in South Korea (PO)
- 20 Jan 2023 YPN 005 is still in preclinical phase for Acute myeloid leukaemia (PO) in South Korea (Yungjin Pharma pipeline, January 2023)
- 10 Dec 2022 Pharmacodynamics data from a preclinical phase in Acute Myeloid Leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)